Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Aug;27(8):e15295.
doi: 10.1111/1756-185X.15295.

Effect of the Janus kinase inhibitor tofacitinib in the treatment of juvenile scleroderma: A single-center experience

Affiliations

Effect of the Janus kinase inhibitor tofacitinib in the treatment of juvenile scleroderma: A single-center experience

Lara Colussi et al. Int J Rheum Dis. 2024 Aug.
No abstract available

PubMed Disclaimer

References

REFERENCES

    1. Li SC. Scleroderma in children and adolescents: localized scleroderma and systemic sclerosis. Pediatr Clin N Am. 2018;65(4):757‐781. doi:10.1016/j.pcl.2018.04.002
    1. McGaugh S, Kallis P, de Benedetto A, Thomas RM. Janus kinase inhibitors for treatment of morphea and systemic sclerosis: a literature review. Dermatol Ther. 2022;35(6):e15437. doi:10.1111/dth.15437
    1. Wang W, Bhattacharyya S, Marangoni RG, et al. The JAK/STAT pathway is activated in systemic sclerosis and is effectively targeted by tofacitinib. J Scleroderma Relat Disord. 2020;5(1):40‐50. doi:10.1177/2397198319865367
    1. Moriana C, Moulinet T, Jaussaud R, Decker P. JAK inhibitors and systemic sclerosis: a systematic review of the literature. Autoimmun Rev. 2022;21(10):103168. doi:10.1016/j.autrev.2022.103168
    1. George R, George A, Kumar TS. Update on management of morphea (localized scleroderma) in children. Indian Dermatol Online J. 2020;11(2):135‐145. doi:10.4103/idoj.IDOJ_284_19

Supplementary concepts

LinkOut - more resources